Ryan Wallace , Ryan Kabir , Sumbal Janjua , Patrick Bering , Toby Rogers
{"title":"回到原点：间隔缩小治疗在马夫卡坦时代的作用","authors":"Ryan Wallace , Ryan Kabir , Sumbal Janjua , Patrick Bering , Toby Rogers","doi":"10.1016/j.crmic.2025.100066","DOIUrl":null,"url":null,"abstract":"<div><div>An 86-year-old-female with hypertrophic cardiomyopathy with persistent obstructive symptoms despite beta blockers and disopyramide was trialed on mavacamten. Although she had improvement in obstructive symptoms, mavacamten was stopped due to reduction in left ventricular ejection fraction even on the lowest dose. Instead, alcohol septal ablation was pursued. This case highlights key considerations surrounding septal reduction therapy in the era of mavacamten.</div></div>","PeriodicalId":100217,"journal":{"name":"Cardiovascular Revascularization Medicine: Interesting Cases","volume":"7 ","pages":"Article 100066"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Back to square one: the role of septal reduction therapy in the era of Mavacamten\",\"authors\":\"Ryan Wallace , Ryan Kabir , Sumbal Janjua , Patrick Bering , Toby Rogers\",\"doi\":\"10.1016/j.crmic.2025.100066\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>An 86-year-old-female with hypertrophic cardiomyopathy with persistent obstructive symptoms despite beta blockers and disopyramide was trialed on mavacamten. Although she had improvement in obstructive symptoms, mavacamten was stopped due to reduction in left ventricular ejection fraction even on the lowest dose. Instead, alcohol septal ablation was pursued. This case highlights key considerations surrounding septal reduction therapy in the era of mavacamten.</div></div>\",\"PeriodicalId\":100217,\"journal\":{\"name\":\"Cardiovascular Revascularization Medicine: Interesting Cases\",\"volume\":\"7 \",\"pages\":\"Article 100066\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Revascularization Medicine: Interesting Cases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2950275625000127\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Revascularization Medicine: Interesting Cases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950275625000127","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Back to square one: the role of septal reduction therapy in the era of Mavacamten
An 86-year-old-female with hypertrophic cardiomyopathy with persistent obstructive symptoms despite beta blockers and disopyramide was trialed on mavacamten. Although she had improvement in obstructive symptoms, mavacamten was stopped due to reduction in left ventricular ejection fraction even on the lowest dose. Instead, alcohol septal ablation was pursued. This case highlights key considerations surrounding septal reduction therapy in the era of mavacamten.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
